Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models

Monday, November 13, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the efficacy of the STING agonist ALG-031048 in inducing tumor regression in mouse models. The results highlight the effectiveness of both intratumoral and subcutaneous dosing methods. These findings suggest a potential advancement in cancer treatment options, warranting further investigation into the therapeutic applications of ALG-031048.
Price reaction · baseline $17.4675 (2023-11-10 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close
-14.1%
day 1 · peak
-15.3%
day 3
-11%

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated tumor regression in mouse models.
  • Promising results from intratumoral and subcutaneous dosing.
  • Potential for further development in cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-031048?

ALG-031048 is a STING agonist being studied for its potential in cancer therapy.

How was ALG-031048 tested?

It was tested in mouse efficacy models using intratumoral and subcutaneous dosing.

What were the results of the study?

The study showed significant tumor regression in the tested mouse models.

What is the significance of these findings?

These findings suggest potential advancements in cancer treatment options.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-031048 STING agonist tumor regression cancer therapy mouse models
Last updated: Nov 13, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →